EcoDrugPlus

Serine/threonine-Protein Phosphatase 2b Catalytic Subunit Alpha Isoform

Ensembl ID : ENSHCOG00000001429
Gene Symbol: LOC109511881
2 Cross references
233 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSHCOG00000007363
Gene Symbol: LOC109529010
2 Cross references
350 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSHCOG00000007353
Gene Symbol: LOC109529009
2 Cross references
350 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSHCOG00000011773
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSHCOG00000006291
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSHCOG00000004547
Gene Symbol: SIRT1
1 Cross references
146 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSHCOG00000004534
Gene Symbol: SIRT1
3 Cross references
146 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSHCOG00000014350
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSHCOG00000015345
Gene Symbol: LOC109512821
3 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSHCOG00000009298
Gene Symbol: SCN8A
2 Cross references
215 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSHCOG00000020660
Gene Symbol: SCN8A
4 Cross references
216 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSHCOG00000003383
Gene Symbol: LOC109507276
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).